Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by SouthernTierTomon Mar 31, 2022 9:01pm
165 Views
Post# 34565322

RE:So far one of the Biggest "foundations" appears to have been

RE:So far one of the Biggest "foundations" appears to have beenIt was actually our partner from the MEDIC Trial that invented the MODs system. I'm sure it is a wonderful way to "score dysfuntional organs", but considering PMX benefits are so much about the ability to stabilize and improve BP, it kind of feels like using MODs "handcuffed" PMX efficacy on so many levels... not to mention SOFA seems so much more widely used. Interesting, I wonder if our choice to go "MODs" was partly about supporting a former clinical partner?  Our partnerships have often been beneficial to insider ACBs.. seldomly to building shareholder value.   Hmmmmm. As long as someone "wins", well then that is most important.  Now that we've "listened to what global clinical giants want" ( see U of M, Louisiana St, Cleveland Clinic, Stanford etc..) perhaps we will start capitalizing on the "exceeding expectation"... "hence forth" ;  - )

T
<< Previous
Bullboard Posts
Next >>